311 related articles for article (PubMed ID: 21918980)
21. Liver X receptor regulates expression of MRP2 but not that of MDR1 and BCRP in the liver.
Chisaki I; Kobayashi M; Itagaki S; Hirano T; Iseki K
Biochim Biophys Acta; 2009 Nov; 1788(11):2396-403. PubMed ID: 19728987
[TBL] [Abstract][Full Text] [Related]
22. Variation and evolution of the ABC transporter genes ABCB1, ABCC1, ABCG2, ABCG5 and ABCG8: implication for pharmacogenetics and disease.
Silverton L; Dean M; Moitra K
Drug Metabol Drug Interact; 2011; 26(4):169-79. PubMed ID: 22098604
[TBL] [Abstract][Full Text] [Related]
23. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Marchetti S; de Vries NA; Buckle T; Bolijn MJ; van Eijndhoven MA; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Mol Cancer Ther; 2008 Aug; 7(8):2280-7. PubMed ID: 18723475
[TBL] [Abstract][Full Text] [Related]
24. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.
Fischer S; Lakatos PL; ; Lakatos L; Kovacs A; Molnar T; Altorjay I; Papp M; Szilvasi A; Tulassay Z; Osztovits J; Papp J; Demeter P; Schwab R; Tordai A; Andrikovics H
Scand J Gastroenterol; 2007 Jun; 42(6):726-33. PubMed ID: 17505995
[TBL] [Abstract][Full Text] [Related]
25. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.
Miura M; Kagaya H; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Ther Drug Monit; 2008 Oct; 30(5):559-64. PubMed ID: 18695635
[TBL] [Abstract][Full Text] [Related]
26. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
Kopp TI; Andersen V; Tjonneland A; Vogel U
Scand J Gastroenterol; 2015; 50(12):1469-81. PubMed ID: 26109419
[TBL] [Abstract][Full Text] [Related]
28. Association Between ABCG2, ABCB1, ABCC2 Efflux Transporter Single-Nucleotide Variants and Irinotecan Adverse Effects in Patients With Colorectal Cancer: A Real-Life Study.
Barnett-Griness O; Rennert G; Lejbkowicz F; Pinchev M; Saliba W; Gronich N
Clin Pharmacol Ther; 2023 Mar; 113(3):704-711. PubMed ID: 36537755
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
30. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
31. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
[TBL] [Abstract][Full Text] [Related]
32. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
33. Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.
Strouse JJ; Ivnitski-Steele I; Waller A; Young SM; Perez D; Evangelisti AM; Ursu O; Bologa CG; Carter MB; Salas VM; Tegos G; Larson RS; Oprea TI; Edwards BS; Sklar LA
Anal Biochem; 2013 Jun; 437(1):77-87. PubMed ID: 23470221
[TBL] [Abstract][Full Text] [Related]
34. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
[TBL] [Abstract][Full Text] [Related]
35. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
36. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
37. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183".
Marchetti S; Pluim D; Beijnen JH; Mazzanti R; van Tellingen O; Schellens JH
Invest New Drugs; 2014 Dec; 32(6):1083-95. PubMed ID: 25078948
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.
Andersen V; Ostergaard M; Christensen J; Overvad K; Tjønneland A; Vogel U
BMC Cancer; 2009 Nov; 9():407. PubMed ID: 19930591
[TBL] [Abstract][Full Text] [Related]
39. TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.
Bhagyaraj E; Ahuja N; Kumar S; Tiwari D; Gupta S; Nanduri R; Gupta P
Cell Cycle; 2019 Dec; 18(24):3589-3602. PubMed ID: 31739702
[TBL] [Abstract][Full Text] [Related]
40. Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury.
Cousar JL; Conley YP; Willyerd FA; Sarnaik AA; Puccio AM; Empey PE; Kochanek PM; Bell MJ; Okonkwo DO; Clark RS
Neurocrit Care; 2013 Oct; 19(2):192-8. PubMed ID: 23896815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
